PDCD1 and familial pancreatic carcinoma: This appears to be particularly true for malignancies of the GI tract where anti-PD-1 mAb has activity in the esophageal and gastric cancers, but no activity in the colon (except those carrying microsatellite instabilities) and pancreatic cancers.